Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04580043
Other study ID # STUDY19090219 (Part 2)
Secondary ID R01MH124707
Status Recruiting
Phase N/A
First received
Last updated
Start date December 28, 2020
Est. completion date January 2, 2027

Study information

Verified date July 2023
Source University of Pittsburgh
Contact Rebecca Price, PhD
Phone 4126486445
Email canlab@pitt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project seeks to identify causal neural mechanisms underlying unwanted, repetitive behaviors (compulsions). Using non-invasive brain stimulation coupled with practice in a computer task, we will modulate activity in a target brain region and measure effects on compulsive behaviors and related measures. This work could ultimately lead to the ability to treat compulsions more effectively by targeting the regions of the brain that can help or hinder attempts to overcome compulsions.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 2, 2027
Est. primary completion date January 2, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Participants will: 1. Be between the ages of 18 and 60 years 2. Endorse problematic compulsive behaviors, per self-report and clinician-administered measures. 3. Agree to video taping of structured clinical interview 4. Report that they will reside in the Pittsburgh area for at least 5 weeks Exclusion Criteria: 1. Failure to meet standard MRI inclusion criteria: those who endorse claustrophobia, those who have cardiac pacemakers, neural pacemakers, surgical clips in the brain or blood vessels, surgically implanted metal plates, screws or pins, cochlear implants, implanted uterine devices, metal braces, or other metal objects in their body, especially in the eye. Dental fillings do not present a problem. Plastic or removable dental appliances do not require exclusion. History of significant injury or surgery to the brain or spinal cord that would impair interpretation of results. Pregnancy, determined by pregnancy tests on females. 2. Medical contraindications for Transcranial Magnetic Stimulation (TMS): 1. Presence of a neurologic disorder or medication therapy known to alter seizure threshold (e.g., stroke, aneurysm, brain surgery, structural brain lesion, brain injury, frequent/severe headaches) 2. Recurrent seizures or epilepsy in participant or family history of hereditary epilepsy 3. Pregnancy 4. Metallic implants in body or other devices that may be affected by magnetic field 5. Significant heart disease or cerebrovascular disease 6. Medications with seizure threshold lowering potential, e.g., clomipramine, Monoamine Oxidase inhibitors (MAOi's), imipramine, clozapine 3. Acute suicidality or other psychiatric crises requiring treatment escalation 4. Changes made to treatment regimen within 4 weeks of baseline assessment 5. Reading level <6th grade 6. Presence of bipolar, psychotic, autism spectrum, or substance use disorder (i.e. current use of mood altering drugs such as cocaine, cannabis or marijuana, opiates, amphetamines, and barbiturates) 7. Presence of movement disorder or tics affecting manual responses 8. Inability to read text from 2 feet away (corrective lenses allowed)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Habit Override Practice
Computerized "brain training" to provide practice in overriding avoidance habits.
Device:
Transcranial Magnetic Stimulation
Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
Behavioral:
Sham Training
Computer-based task practice in a non-active/inert task.
Device:
Sham Transcranial Magnetic Stimulation
Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.

Locations

Country Name City State
United States Western Psychiatric Institute and Clinic Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Rebecca Price National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain activation in target region Mean Cerebral Blood Flow (CBF) in orbitofrontal cortex collected via functional Magnetic Resonance Imaging (fMRI) 10-60min post-intervention
Primary Effort to resist compulsive behaviors in response to laboratory triggers Custom-made laboratory assessment of ability to override compulsive behaviors in response to idiographic triggers: self-reported effort needed to resist (0-100 scale) 60min post-intervention
Primary Duration of compulsive behaviors in response to laboratory triggers Custom-made laboratory assessment of ability to override compulsive behaviors in response to idiographic triggers: duration of compulsive behavior performance (% of total time allotted) 60min post-intervention
Primary Intensity of urges to perform compulsive behaviors in response to laboratory triggers Custom-made laboratory assessment of ability to override compulsive behaviors in response to idiographic triggers: self-reported urge intensity (0-100 scale) 60min post-intervention
Secondary Goal-directed cognition Neuropsychological test of flexible goal-directed cognition (two-step task): switch score (higher score=better performance) 90min-1 week
Secondary Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Clinician-administered measurement of obsessions and compulsions (range: 0-40; higher score=worse outcome) 1 week
Secondary WHO Disability Assessment Scale 2.0 Self-report measure of general functioning and disability (0-100; higher score=worse outcome) 1 week
Secondary Obsessive Compulsive Inventory-Revised (OCI-R) Self-report measure of obsessions and compulsions (0-72; higher score=worse outcome) 1 week
Secondary Effort to resist compulsive behaviors in response to laboratory triggers Custom-made laboratory assessment of ability to override compulsive behaviors in response to idiographic triggers: self-reported effort needed to resist (0-100 scale) 1 week
Secondary Duration of compulsive behaviors in response to laboratory triggers Custom-made laboratory assessment of ability to override compulsive behaviors in response to idiographic triggers: duration of compulsive behavior performance (% of total time allotted) 1 week
Secondary Intensity of urges to perform compulsive behaviors in response to laboratory triggers Custom-made laboratory assessment of ability to override compulsive behaviors in response to idiographic triggers: self-reported urge intensity (0-100 scale) 1 week
Secondary Brain activation in target region Mean Cerebral Blood Flow (CBF) in orbitofrontal cortex collected via functional Magnetic Resonance Imaging (fMRI) 1 week
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3